Items tagged with Treatment
New drug-resistant TB treatments reach patients in Pakistan as Association for Social Development accelerates pilot implementation (post)
ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social Development (ASD) has registered 206 participants with drug-resistant tuberculosis (DR-TB) in Pakistan through a pilot program for treatment with new regimens recently recommended by the World Health Organization (WHO), known as BPaL/M – combinations of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin. ASD reported that out of 113 treatment outcomes declared, so far 105 (95%) have been successful—matching the success rates found elsewhere in the world with these new regimens and a drastic improvement over results with prior drug-resistant TB therapies. As an outcome of these positive results, Pakistan has updated its treatment guidelines for DR-TB to enable the use of these six-month, all-oral regimens.
TB-PRACTECAL trial reveals efficacy of new oral regimen (post)
In a recent study published in The Lancet Respiratory Medicine, researchers reported the TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline, linezolid, and pretomanid (BPaL)-based regimens for pulmonary tuberculosis resistant to rifampicin.
Standards for clinical trials for treating TB (post)
The value, speed of completion and robustness of the evidence generated by TB treatment clinical trials could be improved by implementing standards for best practice.
Adverse outcomes in drug-resistant TB with diabetes (post)
Diabetes mellitus may lead to adverse outcomes in multidrug-resistant tuberculosis (MDR-TB) or DR-TB, according to systematic review and meta-analysis findings published in BMC Infectious Diseases.
Experts project growth in uptake of shorter, all-oral regimens for drug-resistant TB (post)
A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.
Lung problems persist in most adolescents even after TB treatment (post)
Two out of three adolescents diagnosed with pulmonary tuberculosis (TB) experience lung abnormalities even after successfully completing treatment for this disease.
New mobile app proves effective in enhancing TB drug adherence (post)
In a recent study published in the journal BMC Public Health, a team of researchers from Malaysia described a mobile phone application called Gamified-Real-Time Video Observed Therapy or GRVOTS designed to motivate tuberculosis patients to adhere to their treatment regimen through improved patient tracking and enhanced engagement with their doctors through the mobile application.
Multimodal AI model may guide personalized treatments for TB (post)
A team of University of Michigan researchers, led by Sriram Chandrasekaran, Associate Professor, Biomedical Engineering, and postdoctoral fellow Awanti Sambarey developed a multimodal AI model to predict treatment outcomes of tuberculosis (TB) patients. Their analysis of real-world worldwide patient data may lead to personalization of TB treatment.
ACTG announces launch of clinical trial evaluating drug-drug interaction in shortened TB regimen among people living with HIV (post)
LOS ANGELES, Feb. 14, 2024 -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis). A5406 is a phase 2, open-label pharmacokinetic study investigating the effect that the anti-tuberculosis (TB) medication rifapentine has on levels of the HIV medication dolutegravir in the blood of participants who have HIV-associated TB and whether this combination can be safely and effectively used together.
Drug-resistant TB responds rapidly to bedaquiline-based second-line therapy (post)
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO in Haiti. Second-line medications are those that are given when one or more of the drugs given first for the disease are not effective. The research could have implications for shortening the duration of treatment for drug-resistant TB, which currently requires medications for up to 2 years, while those with drug-sensitive TB complete treatment in about 6 months.
Page 73 of 105 · Total posts: 0
←First 72 73 74 Last→